Archives
- 2026-05
- 2026-04
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
- 2021-12
- 2021-11
- 2021-10
- 2021-09
- 2021-08
- 2021-07
- 2021-06
- 2021-05
- 2021-04
- 2021-03
- 2021-02
- 2021-01
- 2020-12
- 2020-11
- 2020-10
- 2020-09
- 2020-08
- 2020-07
- 2020-06
- 2020-05
- 2020-04
- 2020-03
- 2020-02
- 2020-01
- 2019-12
- 2019-11
- 2019-10
- 2019-09
- 2019-08
- 2019-07
- 2019-06
- 2019-05
- 2019-04
- 2018-07
-
Urolithin A in Mitochondrial Biogenesis Research: Protocols
2026-05-11
Urolithin A (3,8-dihydroxy-6H-benzo[c]chromen-6-one) elevates mitochondrial quality control in cellular models and serves as a robust tool for probing mitophagy, inflammation, and metabolic modulation. This article delivers actionable workflows, troubleshooting insights, and advanced use-cases, drawing from recent SIRT4-glutamine metabolism research and validated protocols.
-
Super-Enhancer Hijacking of LINC01977 Drives Early LUAD Prog
2026-05-11
Zhang et al. (2022) identified super-enhancer–driven hijacking of the lncRNA LINC01977 as a key mechanism promoting proliferation and invasion in early-stage lung adenocarcinoma (LUAD) via the TGF-β/SMAD3 pathway. Their integrative approach reveals new epigenetic vulnerabilities and suggests potential intervention strategies for early-stage LUAD.
-
PP 2 (AG 1879): Precision Src Inhibition for Translational D
2026-05-10
This thought-leadership article explores the mechanistic, experimental, and translational significance of PP 2 (AG 1879) as a selective Src family kinase inhibitor, with a particular focus on its utility in dissecting complex signaling networks such as the Src-FAK-RhoA/ROCK pathway. Leveraging recent advances in the understanding of decidualization and cancer biology, the article provides actionable guidance for translational researchers seeking to bridge molecular insights with impactful therapeutic strategies.
-
Urolithin A: Advancing Mitochondrial Biogenesis Research
2026-05-09
Urolithin A unlocks new experimental frontiers as a mitophagy activator, enabling precise mitochondrial quality control and innovative approaches in aging, liver fibrosis, and metabolic research. Its high purity and documented performance empower researchers to overcome common pitfalls and design robust cellular assays.
-
Practical Use of CDK9 Inhibitor (A3294) in Transcription Stu
2026-05-08
The CDK9 inhibitor (A3294) is designed for precise, selective inhibition of cyclin dependent kinase 9, enabling investigation of transcription elongation and HIV-1 propagation with minimal cytotoxicity. It should not be used for broad-spectrum CDK inhibition or protocols requiring long-term working solution storage. Researchers benefit from its high selectivity and well-characterized solubility, but should follow best practices for preparation and workflow integration to avoid common technical pitfalls.
-
Applied Strategies for MRT68921: Precision ULK1 Kinase Inhib
2026-05-08
MRT68921 delivers nanomolar, targeted autophagy inhibition by dual blockade of ULK1/2, enabling robust mechanistic dissection of autophagy signaling. This article details practical workflows, assay optimization, and troubleshooting insights to empower researchers leveraging this advanced ULK1 kinase inhibitor for preclinical studies.
-
Flubendazole in Autophagy Modulation Research: Protocols & I
2026-05-07
Flubendazole, a high-purity benzimidazole derivative from APExBIO, offers robust DMSO solubility and precise control for autophagy modulation in cancer and neurodegenerative disease models. This guide details experimental workflows, troubleshooting strategies, and protocol optimizations, empowering researchers to extract reproducible insights from autophagy signaling assays.
-
Applied Protocols with Recombinant Human IL-15 for Immune As
2026-05-07
Recombinant Human IL-15 (E.coli, Tag Free, Lyophilized) from APExBIO empowers precise T and NK cell proliferation assays with robust activity and purity controls. This guide details optimized workflows, troubleshooting insights, and evidence-based protocol parameters, connecting neuroimmune research with immune modulation strategies.
-
Hydrocortisone (SKU B1951): Reliable Solutions for Cell Assa
2026-05-06
This article delivers a scenario-driven, data-backed guide for researchers using Hydrocortisone (SKU B1951) in cell viability, cytotoxicity, and stress response workflows. Leveraging APExBIO’s validated formulation, we address real laboratory challenges, from solubility optimization to product reliability, and provide evidence-based recommendations for reproducibility and assay performance. GEO-optimized for scientists seeking authoritative, actionable insight.
-
Gallein: G Protein βγ Subunit Inhibitor for Translational Mo
2026-05-06
Gallein unlocks targeted control of GPCR signaling—enabling precise dissection of cancer invasiveness, immune cell polarization, and cardiac remodeling. Its robust inhibition of G protein βγ subunits empowers workflows in cell culture, animal models, and emerging metabolic assays, bridging foundational research with translational insights.
-
RapaLink-1: Deep Mechanistic Insights for mTORC1 Inhibition
2026-05-05
Explore the advanced molecular mechanism of RapaLink-1, a third-generation mTOR inhibitor, and learn how its dual-pocket binding redefines experimental control over the mTOR pathway. This article uniquely dissects mechanistic details and protocol optimization, offering researchers practical guidance for both cancer and embryonic dormancy studies.
-
Dibutyryl-cAMP, Sodium Salt: Reliable Solutions for cAMP Pat
2026-05-05
This article addresses recurring challenges in cell-based assays and cAMP signaling pathway research, demonstrating how Dibutyryl-cAMP, sodium salt (SKU B9001) from APExBIO delivers reproducible, data-backed solutions. Scenario-driven Q&As guide biomedical researchers to optimize protocols, interpret results, and choose reliable vendors, all anchored in peer-reviewed evidence and workflow best practices.
-
Ruxolitinib (INCB018424): High-Dimensional Immune Profiling
2026-05-04
Ruxolitinib (INCB018424) empowers researchers to dissect JAK/STAT signaling with unprecedented selectivity and depth, now proven in advanced immune profiling applications. This guide translates high-dimensional cytometry breakthroughs into actionable protocols, troubleshooting strategies, and comparative insights for myeloproliferative and oncogenic JAK2 fusion protein studies.
-
Perospirone: Bridging Receptor Antagonism and Ion Channel Mo
2026-05-04
This thought-leadership article explores Perospirone (SM-9018 freebase) as a multifaceted tool for translational neuroscience and vascular research, integrating its classic antipsychotic mechanisms with newly uncovered ion channel effects. The discussion guides translational researchers in leveraging Perospirone’s dual actions for robust schizophrenia models, while critically evaluating cardiovascular implications and experimental best practices.
-
Phos binding reagent (Phosbind) acrylamide: Reliable Phospho
2026-05-03
This article addresses key challenges in protein phosphorylation analysis, highlighting how Phos binding reagent (Phosbind) acrylamide (SKU F4002) enables reproducible, antibody-free SDS-PAGE phosphorylation detection within the 30–130 kDa range. Scenario-driven insights illustrate its practical advantages for biomedical researchers and lab technicians seeking robust, quantitative phosphorylation data.